Myomo (MYO) Return on Capital Employed (2017 - 2025)
Myomo (MYO) posted Return on Capital Employed of 43.7% for Q3 2025, down 31.44% on a QoQ basis from 33.24% in Q2 2025, and up 4696.0% year-over-year from 0.91% in Q3 2024.
Myomo (MYO) Return on Capital Employed (2017 - 2025) Analysis & Trends
Myomo's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 43.7% for Q3 2025.
- Quarterly Return on Capital Employed rose 4696.0% year-over-year to 43.7% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 43.7% (up 4696.0% YoY) and the FY2024 annual result came in at 34.03%, up 8536.0% from the prior year.
- Return on Capital Employed was 43.7% for Q3 2025 at Myomo, down from 33.24% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 19.54% in Q1 2025 and bottomed at 141.35% in Q4 2022.
- A 5-year average of 78.44% and a median of 79.6% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed jumped 8885 bps — and 2022, when it sank 7050 bps.
- Myomo's Return on Capital Employed stood at 70.84% in 2021, then tumbled by 100 bps to 141.35% in 2022, then jumped by 44 bps to 79.6% in 2023, then surged by 59 bps to 32.48% in 2024, then sank by 35 bps to 43.7% in 2025.
- Business Quant data shows MYO's Return on Capital Employed at 43.7% in Q3 2025, 33.24% in Q2 2025, and 19.54% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Myomo | 39.24 Mn | 20.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -43.70% |
| Jun 30, 2025 | -33.24% |
| Mar 31, 2025 | -19.54% |
| Dec 31, 2024 | -32.48% |
| Sep 30, 2024 | -90.65% |
| Jun 30, 2024 | -95.66% |
| Mar 31, 2024 | -94.54% |
| Dec 31, 2023 | -79.60% |
| Sep 30, 2023 | -85.42% |
| Jun 30, 2023 | -96.11% |
| Mar 31, 2023 | -132.44% |
| Dec 31, 2022 | -141.35% |
| Sep 30, 2022 | -120.69% |
| Jun 30, 2022 | -83.74% |
| Mar 31, 2022 | -70.04% |
| Dec 31, 2021 | -70.84% |
| Sep 30, 2021 | -66.72% |
| Jun 30, 2021 | -60.66% |
| Mar 31, 2021 | -72.98% |
| Dec 31, 2020 | -86.35% |